At a glance
ClinicalIndex Comparison RecordN/ACompleted· 210 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Investigation of Genetic Variations on Patients With Adverse Events While on Direct Oral Anticoagulants (DOACs)
In Brief
An observational study for Drug-Related Side Effects and Adverse Reactions and Treatment Failure. Completed, enrolled 210 participants across 1 site.
Detailed Summary
The purpose of this study is to see if the participant's genetic profile and clinical factors (age, drug dose, etc.) affect drug outcomes (i.e. serious bleeding) that the participant may have experienced since taking the drug (direct oral anticoagulant) for preventing blood clots from forming in the blood vessels.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
CollaboratorsSanta Clara Valley Medical Center
Timeline
N/ACompletedFinished
202120222023202420252026
First PostedOct 2020
Enrollment StartFeb 2021
Primary CompletionOct 2022
TodayJul 2026
First PostedOct 8, 2020
Enrollment StartFeb 1, 2021
Primary CompletionOct 31, 2022
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 5.7 years ago